MX2018003861A - Nuevos derivados de pirrolo[2,3-d]pirimidina, un proceso para su preparacion y composiciones farmaceuticas que los contienen. - Google Patents

Nuevos derivados de pirrolo[2,3-d]pirimidina, un proceso para su preparacion y composiciones farmaceuticas que los contienen.

Info

Publication number
MX2018003861A
MX2018003861A MX2018003861A MX2018003861A MX2018003861A MX 2018003861 A MX2018003861 A MX 2018003861A MX 2018003861 A MX2018003861 A MX 2018003861A MX 2018003861 A MX2018003861 A MX 2018003861A MX 2018003861 A MX2018003861 A MX 2018003861A
Authority
MX
Mexico
Prior art keywords
pyrimidine derivatives
new pyrrolo
dyrk1
dual
clk1
Prior art date
Application number
MX2018003861A
Other languages
English (en)
Inventor
Kotschy ANDRÁS
Ray Stuart
Humberto CRUZALEGUI Francisco
Foloppe Nicolas
Walmsley David
Frank Burbridge Michaël
Fiumana Andrea
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of MX2018003861A publication Critical patent/MX2018003861A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos de fórmula (I): (ver Fórmula) en la que R1, R2, W3, W4, A1, y A2 son como se definen en la descripción.
MX2018003861A 2015-09-30 2016-09-30 Nuevos derivados de pirrolo[2,3-d]pirimidina, un proceso para su preparacion y composiciones farmaceuticas que los contienen. MX2018003861A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1559259A FR3041640B1 (fr) 2015-09-30 2015-09-30 NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
PCT/EP2016/073403 WO2017055533A1 (en) 2015-09-30 2016-09-30 New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors

Publications (1)

Publication Number Publication Date
MX2018003861A true MX2018003861A (es) 2018-08-16

Family

ID=54979756

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003861A MX2018003861A (es) 2015-09-30 2016-09-30 Nuevos derivados de pirrolo[2,3-d]pirimidina, un proceso para su preparacion y composiciones farmaceuticas que los contienen.

Country Status (26)

Country Link
US (1) US20180273538A1 (es)
EP (1) EP3356364A1 (es)
JP (1) JP2018533552A (es)
KR (1) KR20180054856A (es)
CN (1) CN108137582A (es)
AU (1) AU2016333508A1 (es)
BR (1) BR112018005851A2 (es)
CA (1) CA2999937A1 (es)
CL (1) CL2018000786A1 (es)
CO (1) CO2018003466A2 (es)
CR (1) CR20180176A (es)
CU (1) CU20180027A7 (es)
DO (1) DOP2018000082A (es)
EA (1) EA201890820A1 (es)
EC (1) ECSP18023286A (es)
FR (1) FR3041640B1 (es)
HK (1) HK1255467A1 (es)
IL (1) IL258231A (es)
MA (1) MA43021A (es)
MX (1) MX2018003861A (es)
NI (1) NI201800042A (es)
PE (1) PE20190337A1 (es)
PH (1) PH12018500605A1 (es)
SV (1) SV2018005656A (es)
TN (1) TN2018000087A1 (es)
WO (1) WO2017055533A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
KR102054910B1 (ko) * 2017-12-19 2019-12-12 한림제약(주) 피롤로[2,3-d]피리미딘 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CA3118093A1 (en) * 2018-09-28 2020-04-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of dyrk1/clk and uses thereof
PE20211655A1 (es) 2018-10-31 2021-08-24 Gilead Sciences Inc Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
CN110407744A (zh) * 2019-08-13 2019-11-05 上海毕得医药科技有限公司 一种1-(4-氨基吡啶-2-基)乙酮的合成方法
AR120799A1 (es) * 2019-12-20 2022-03-16 Hoffmann La Roche 2-[4-cloro-6-[2-[4-[[4-(hidroximetil)-1-piperidil]metil]fenil]etinil]-1-oxoisoindolin-2-il]-2-(6,7-dihidro-5h-pirrolo[1,2-c]imidazol-1-il)-n-tiazol-2-il-acetamida como inhibidor de egfr
WO2022245776A1 (en) * 2021-05-20 2022-11-24 Saint John's Cancer Institute Anti-cdk inhibitors for cancer treatment
AU2022367221A1 (en) * 2021-10-12 2024-05-02 Biosplice Therapeutics, Inc. 7h-pyrrolo[2,3-d]pyrimidines and preparation as dyrk1a inhibitors
US20230192686A1 (en) * 2021-10-12 2023-06-22 Biosplice Therapeutics, Inc. 1h-pyrrolo[2,3-b]pyridines and preparation and uses thereof
WO2023110843A1 (en) * 2021-12-15 2023-06-22 Almirall, S.A. Heterobicyclic derivatives as itk inhibitors
CN116621843B (zh) * 2022-06-13 2024-05-24 四川大学华西医院 一种dna甲基转移酶1抑制剂及其制备方法和用途
CN115785134B (zh) * 2022-10-28 2023-08-29 浙大城市学院 一种含氮杂环的硼酸化合物及制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ564283A (en) 2005-05-20 2011-07-29 Methylgene Inc Inhibitors of VEGF receptor and HGF receptor signaling
CA2625109A1 (en) 2005-10-13 2007-04-19 Glaxo Group Limited Pyrrolopyrimidine derivatives as syk inhibitors
CA2645343A1 (en) 2006-03-11 2007-09-20 Vernalis (R&D) Limited Pyrrolopyrimidine derivatives used as hsp90 inhibitors
FR2912744B1 (fr) * 2007-02-16 2012-09-07 Centre Nat Rech Scient Composes pyrrolo°2,3-b!pyridine,composes azaindoles utiles dans la synthese de ces composes pyrrolo°2,3-b!pyridine, leurs procedes de fabrication et leurs utilisations.
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
AU2013282869B2 (en) * 2012-06-29 2015-12-24 Pfizer Inc. Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors
US9695171B2 (en) * 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors

Also Published As

Publication number Publication date
CO2018003466A2 (es) 2018-07-10
PH12018500605A1 (en) 2018-09-24
HK1255467A1 (zh) 2019-08-16
CA2999937A1 (en) 2017-04-06
MA43021A (fr) 2018-08-08
FR3041640B1 (fr) 2019-05-17
SV2018005656A (es) 2018-08-10
CL2018000786A1 (es) 2018-09-28
KR20180054856A (ko) 2018-05-24
EA201890820A1 (ru) 2018-10-31
CR20180176A (es) 2018-05-31
IL258231A (en) 2018-05-31
BR112018005851A2 (pt) 2018-10-09
CN108137582A (zh) 2018-06-08
NI201800042A (es) 2018-06-21
AU2016333508A1 (en) 2018-04-12
US20180273538A1 (en) 2018-09-27
PE20190337A1 (es) 2019-03-07
EP3356364A1 (en) 2018-08-08
TN2018000087A1 (en) 2019-07-08
DOP2018000082A (es) 2018-10-15
FR3041640A1 (es) 2017-03-31
CU20180027A7 (es) 2018-07-05
JP2018533552A (ja) 2018-11-15
ECSP18023286A (es) 2018-04-30
WO2017055533A1 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
MX2018003861A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
MA39986A (fr) Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
MX2015000129A (es) Derivados de pirimidin pirazolilo.
GEP20217211B (en) Substituted carbonucleoside derivatives useful as anticancer agents
MY197626A (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
MX2018003860A (es) Nuevos derivados de imidazo[4,5-b]piridina, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
PH12014502032A1 (en) Treatment of brain cancer
EP3380471B8 (en) Tetrahydro-8h-pyrido[1,2-a]pyrazine-8-ones as comt inhibitors for the treatment of neurodegenerative disorders
EP3283463A4 (en) Dimeric quinacrine derivatives as autophagy inhibitors for cancer therapy
MX359656B (es) Derivados de oxoquinazolinil-butanamida.
MX2016014436A (es) Derivados de heterociclil-butanamida.
MX2014008864A (es) Derivados de triazolo[4,5-d]pirimidina.
MX364859B (es) Derivados de imidazopirazinona.
JO3372B1 (ar) مشتقات 5-بنزيل إيزوكينولين لعلاج أمراض القلب والأوعية الدموية
DK3083627T3 (da) [1,2,4]triazol[1,5-a]pyrimidinderivater som protozoiske proteasominhibitorer til behandling af parasitsygdomme, såsom leishmaniasis
MX2018005515A (es) Derivados de 1,4-dicarbonil-piperidilo.
MX2015016760A (es) Derivados de ftalazina.
EP3694521A4 (en) TOPICAL METHOTREXATE SOLUTION FOR TREATMENT OF PSORIASIS
AU2017900290A0 (en) Pyrimidin-2-amine derivatives as therapeutic compounds
LV14663A (lv) Pirolo[1,2-a]hinazolīna atvasinājumu sintēze no N-antranilskābes hidrazīdiem un alfa-ketoskābēm